iTeos Therapeutics to Present Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020             iTeos Therapeutics to Present Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020              Cambridge, MA and Gosselies, Belgium – June 15,...

iTeos Therapeutics Strengthens Leadership Team   iTeos Therapeutics Strengthens Leadership Team   Matthew Gall joins as Chief Financial OfficerDr. Yvonne McGrath joins as Vice President of R&DPhilippe Brantegem joins as Vice President of Human...

iTeos Therapeutics Appoints Ann D. Rhoads to Board of Directors iTeos Therapeutics Appoints Ann D. Rhoads to Board of Directors Cambridge, MA and Gosselies, Belgium – June 1, 2020 – iTeos Therapeutics, a clinical-stage biopharmaceutical company pioneering the...

iTeos Therapeutics to Present at UBS Global Healthcare Conference iTeos Therapeutics to Present at UBS Global Healthcare Conference Gosselies, Belgium and Cambridge, MA – May 13, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel...

iTeos Therapeutics to Present Data at 2018 SITC Annual Meeting iTeos Therapeutics to Present Data at 2018 SITC Annual Meeting Gosselies, Belgium – November 6, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today...